Search Result

Results for "

gastrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Akt (3) Amino Acid Decarboxylase (2) Amino Acid Derivatives (1) Biochemical Assay Reagents (1) Bombesin Receptor (27) CCR (2) Cholecystokinin Receptor (39) Drug Derivative (1) Endogenous Metabolite (2) Ephrin Receptor (3) Fluorescent Dye (3) GCGR (1) HIF/HIF Prolyl-Hydroxylase (3) Histamine Receptor (1) Interleukin Related (3) Na+/K+ ATPase (1) PACAP Receptor (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (7) VEGFR (3)
By Research Areas:	Cancer (31) Cardiovascular Disease (3) Endocrinology (12) Infection (1) Inflammation/Immunology (10) Metabolic Disease (31) Neurological Disease (22)

By Targets:

Adrenergic Receptor (3)

Akt (3)

Amino Acid Decarboxylase (2)

Amino Acid Derivatives (1)

Biochemical Assay Reagents (1)

Bombesin Receptor (27)

CCR (2)

Cholecystokinin Receptor (39)

Drug Derivative (1)

Endogenous Metabolite (2)

Ephrin Receptor (3)

Fluorescent Dye (3)

GCGR (1)

HIF/HIF Prolyl-Hydroxylase (3)

Histamine Receptor (1)

Interleukin Related (3)

Na+/K+ ATPase (1)

PACAP Receptor (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (7)

VEGFR (3)

By Research Areas:

Cancer (31)

Cardiovascular Disease (3)

Endocrinology (12)

Infection (1)

Inflammation/Immunology (10)

Metabolic Disease (31)

Neurological Disease (22)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1097

Gastrin I, human Maximum Cited Publications 17 Publications Verification	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-P2671

*[Leu15]-Gastrin* I (human)**	Cholecystokinin Receptor	Cancer
[Leu15]-Gastrin I (human) is a Gastrin I, human (HY-P1097) peptide hormone derivative, which is trophic for normal gastrointestinal epithelium. Gastrin stimulates growth of gastric adenocarcinoma (gastric cancer) through G-protein-coupled receptor called the cholecystokinin (CCK) or cholecystokinin-B receptors (CCK-BR) that are overexpressed in this malignancy. [Leu15]-Gastrin I (human) is promising for research of gastric cancer .

HY-P0238

Gastrin-Releasing Peptide, human	Bombesin Receptor	Cancer
Gastrin-Releasing Peptide, human (GRP) belongs to the bombesin-like peptide family, and is not a classical hypothalamic-hypophyseal regulatory hormone since it plays only a perfunctory role in the mediation of pituitary hormone release.

HY-P0195

Bombesin 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
Bombesin, a tetradecapeptide, plays an important role in the release of gastrin and the activation of G-protein receptors .

HY-14850

Sograzepide 1 Publications Verification Netazepide; YF 476; YM-220	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC₅₀ of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K_i values of 0.068, 0.62 and 0.19 nM, respectively .

HY-103286

PD176252 2 Publications Verification	Bombesin Receptor	Cancer
PD176252 is a potent antagonist of neuromedin-B preferring (BB₁) and gastrin-releasing peptide-preferring (BB₂) receptor with K_is of 0.17 nM and 1 nM for human BB₁ and BB₂ receptors, and 0.66 nM, 16 nM for Rat BB₁ and BB₂ receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC₅₀s of 0.31 and 0.66 μM in HL-60 cells.

HY-17617

Nastorazepide Z-360	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and *gastrin/CCK-2* receptor antagonist. Nastorazepide inhibits the specific binding of [ ³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .

HY-106840

L-365260 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 is an orally active and selective antagonist of non-peptide *gastrin* and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

HY-125556

Tetragastrin 1 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-115822

α-Fluoromethylhistidine dihydrochloride	Amino Acid Decarboxylase	Neurological Disease Metabolic Disease
α-Fluoromethylhistidine dihydrochloride is an orally active histidine decarboxylase inhibitor. α-Fluoromethylhistidine dihydrochloride depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-Fluoromethylhistidine dihydrochloride abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases *gastrin*-induced histamine efflux from ECL cells. α-Fluoromethylhistidine dihydrochloride does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-Fluoromethylhistidine dihydrochloride inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells .

HY-116216

PD 168368	Bombesin Receptor	Cancer
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the K_i of 15–45 nM . PD 168368 is neuromedin B receptor (NMBR; IC₅₀=96 nM) / gastrin-releasing peptide receptor (GRPR IC₅₀=3500 nM) antagonist . PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC₅₀s of 0.57, 0.24, and 2.7 nM, respectively .

HY-P0107A

RC-3095 TFA 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-N2600

Kuwanon H	Bombesin Receptor	Cancer
Kuwanon H is a flavonoid isolated from Morus alba, which acts as a potent non-peptide bombesin receptor antagonist. Kuwanon H selectively inhibits binding of gastrin releasing peptide CRP to GRP-preferring recepotr, with a K_i value of 290 nM in cells .

HY-B1273

Fenipentol 1-Phenyl-1-pentanol	Fluorescent Dye	Endocrinology
Fenipentol (1-Phenyl-1-pentanol), a synthetic derivative of an ingredient of Curcuma longa that is used as a condiment and dye. Fenipentol is also an orally active choleretic agent that plays an important role in release of secretin, gastrin, and pancreatic secretion of bicarbonate and protein .

HY-P3576A

*Biotin-Gastrin* Releasing Peptide, human TFA**	Fluorescent Dye Bombesin Receptor	Neurological Disease Cancer
Biotin-Gastrin Releasing Peptide, human TFA is a biotinylated gastrin releasing peptide (GRP). Gastrin-releasing peptide (GRP) is a neuropeptide with growth-stimulatory and tumorigenic properties .

HY-103355

YM022 2 Publications Verification	CCR	Metabolic Disease
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the bombesin (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P2416

Gastrin I, rat Rat gastrin-17	Cholecystokinin Receptor	Endocrinology
Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .

HY-P1806A

Gastrin I (1-14), human TFA	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-P1097F

*Biotin-Gastrin-1, human (1-17)*	Cholecystokinin Receptor	Others
Biotin-Gastrin-1, human (1-17) is a biological active peptide. (Biotin-labeled HY-P1097)

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-W1015419

α-FMH α-Fluoromethylhistidine	Amino Acid Decarboxylase	Cardiovascular Disease Neurological Disease
α-FMH (α-Fluoromethylhistidine) is an orally active histidine decarboxylase inhibitor. α-FMH depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-FMH abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases *gastrin*-induced histamine efflux from ECL cells. α-FMH does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-FMH inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells .

HY-P0107

RC-3095 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 is a *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and *gastrin* that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-101764

Lintitript SR 27897	Cholecystokinin Receptor	Metabolic Disease
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC₅₀ of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC₅₀ value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-W343750

[Tyr4]-Bombesin	Bombesin Receptor	Metabolic Disease
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-115974

GRPR antagonist-1	Bombesin Receptor	Cancer
GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC₅₀ of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis, with anticancer activity .

HY-106840A

L-365260 hemihydrate 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide *gastrin* and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .

HY-P11352

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

HY-P1806

Gastrin I (1-14), human	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-U00375

Gastrin/CCK antagonist 1	Cholecystokinin Receptor	Endocrinology
Gastrin/CCK antagonist 1 is an antagonist of *gastrin/CCK*, used for the research of gastrointestinal disorders.

HY-125314

AG-041R	Cholecystokinin Receptor	Endocrinology Cancer
AG-041R is a potent and selective CCK2 Receptor/Gastrin antagonist. AG-041R inhibits gastrin-evoked secretion of pancreastatin with an IC₅₀ of 2.2 nM. AG-041R inhibits cell growth of Mastomys ECL carcinoid tumor cells .

HY-106347

Itriglumide CR 2945	Cholecystokinin Receptor	Inflammation/Immunology
Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC₅₀ of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC₅₀ of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P3446A

*Big Gastrin* I (human) TFA**	Cholecystokinin Receptor	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases .

HY-165498

AU-461	Na+/K+ ATPase	Metabolic Disease
AU-461 is an orally active and reversible inhibitor of the gastric H⁺/K⁺ ATPase with IC₅₀ values for rabbit-derived and pig-derived enzymes are 12.15 μM and 4.20 μM respectively. AU-461 competes with activated cationic K⁺ (Kᵢ = 1.64 μM). AU-461 reduces both histamine-stimulated gastric acid secretion and basal gastric acid secretion in rats. AU-461 inhibits ulcer formation caused by ethanol or sodium hydroxide, and restores the plasma gastrin level to normal. AU-461 can be used for the study of peptic ulcers .

HY-155205

GV150013X	Cholecystokinin Receptor	Neurological Disease
GV150013X is an antagonist for cholecystokinin-2/gastrin receptor (CCK2R), with K_i of 2.29 nM. GV150013X attenuates central nervous disorders, such as anxiety and panic disorder .

HY-129357

CCK-B Receptor Antagonist 2	Cholecystokinin Receptor	Metabolic Disease
CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC₅₀ of 1.82 μM .

HY-P1800

Caerulein, desulfated	Cholecystokinin Receptor	Metabolic Disease
Caerulein, desulfated is the desulfurated form of Caerulein. Caerulein is a decapeptide having the same five carboxyl-terminal amino acids as gastrin and cholecystokinin (CCK) .

HY-121278

Benzotript Benzotriptum	Cholecystokinin Receptor	Inflammation/Immunology Cancer
Benzotript (Benzotriptum) is a cholecystokinin-receptor (CCK) and gastrin receptor antagonist. Benzotript shows antiproliferative effects in human colon carcinoma cell lines .

HY-176150

AMTG-DA1	Bombesin Receptor	Cancer
AMTG-DA1 is a Gastrin-releasing peptide receptor (GRPR) ligand. AMTG-DA1 can be used in the study of cancer .

HY-19290

S-0509	Cholecystokinin Receptor	Others
S-0509 is a selective *CCKB/gastrin* receptor antagonist. S-0509 has a strong anti-secretion effect. S-0509 helps prevent the occurrence of duodenal ulcers .

HY-122968

Brocresine NSD-1065	Endogenous Metabolite	Neurological Disease
Brocresine (NSD-1065) is an orally active histidine decarboxylase inhibitor and inhibits the formation of histamine from histidine. Brocresine is also a L-amino acid decarboxylase inhibitor with both a peripheral and central action. Brocresine inhibits gastric secretory response to administration of exogenous gastrin .

HY-111918

A71378	Cholecystokinin Receptor	Metabolic Disease
A71378 is a selectivity CCK-A receptor agonist the IC₅₀ values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC₅₀ = 0.16 nM) and ileal muscle contraction (EC₅₀ = 3.7 nM) .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the bombesin (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

Cat. No.	Product Name	Type

HY-161565

Gastrin(1-17)/BSA

Biochemical Assay Reagents

Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

Cat. No.	Product Name	Target	Research Area

HY-P1097

Gastrin I, human Maximum Cited Publications 17 Publications Verification	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-P2671

*[Leu15]-Gastrin* I (human)**	Cholecystokinin Receptor	Cancer
[Leu15]-Gastrin I (human) is a Gastrin I, human (HY-P1097) peptide hormone derivative, which is trophic for normal gastrointestinal epithelium. Gastrin stimulates growth of gastric adenocarcinoma (gastric cancer) through G-protein-coupled receptor called the cholecystokinin (CCK) or cholecystokinin-B receptors (CCK-BR) that are overexpressed in this malignancy. [Leu15]-Gastrin I (human) is promising for research of gastric cancer .

HY-P0238

Gastrin-Releasing Peptide, human	Bombesin Receptor	Cancer
Gastrin-Releasing Peptide, human (GRP) belongs to the bombesin-like peptide family, and is not a classical hypothalamic-hypophyseal regulatory hormone since it plays only a perfunctory role in the mediation of pituitary hormone release.

HY-P0195

Bombesin 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
Bombesin, a tetradecapeptide, plays an important role in the release of gastrin and the activation of G-protein receptors .

HY-125556

Tetragastrin 1 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-P0107A

RC-3095 TFA 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P3576A

*Biotin-Gastrin* Releasing Peptide, human TFA**	Fluorescent Dye Bombesin Receptor	Neurological Disease Cancer
Biotin-Gastrin Releasing Peptide, human TFA is a biotinylated gastrin releasing peptide (GRP). Gastrin-releasing peptide (GRP) is a neuropeptide with growth-stimulatory and tumorigenic properties .

HY-P5055

Gastrin I (human) sulfated	Peptides	Others
Gastrin I (human) (sulfated) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the bombesin (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P2416

Gastrin I, rat Rat gastrin-17	Cholecystokinin Receptor	Endocrinology
Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .

HY-P1806A

Gastrin I (1-14), human TFA	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-P1097F

*Biotin-Gastrin-1, human (1-17)*	Cholecystokinin Receptor	Others
Biotin-Gastrin-1, human (1-17) is a biological active peptide. (Biotin-labeled HY-P1097)

HY-103281

Litorin	Bombesin Receptor	Metabolic Disease
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .

HY-P0107

RC-3095 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 is a *bombesin/gastrin* releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and *gastrin* that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-W343750

[Tyr4]-Bombesin	Bombesin Receptor	Metabolic Disease
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .

HY-P1800A

Caerulein, desulfated TFA 2 Publications Verification	Peptides	Metabolic Disease
Caerulein, desulfated TFA is the desulfurated form of Caerulein. Caerulein is a decapeptide having the same five carboxyl-terminal amino acids as gastrin and cholecystokinin (CCK) .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P11352

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

HY-P1806

Gastrin I (1-14), human	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P3446A

*Big Gastrin* I (human) TFA**	Cholecystokinin Receptor	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases .

HY-P1800

Caerulein, desulfated	Cholecystokinin Receptor	Metabolic Disease
Caerulein, desulfated is the desulfurated form of Caerulein. Caerulein is a decapeptide having the same five carboxyl-terminal amino acids as gastrin and cholecystokinin (CCK) .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the bombesin (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-103285

GRP (porcine) Porcine gastrin-releasing peptide 27	Cholecystokinin Receptor	Cancer
GRP (porcine) (Porcine gastrin-releasing peptide 27) is the putative mammalian analog of Bombesin (HY-P0195). GRP (porcine) activates the release of a number of gastroenteropancreatic (GEP) peptides into the peripheral circulation. GRP (porcine) stimulates gastrin release and exocrine pancreatic secretion. GRP (porcine) is a useful marker of neuroendocrine differentiation in many tumors .

HY-P3576

*Biotin-Gastrin* Releasing Peptide, human**	Fluorescent Dye Bombesin Receptor	Neurological Disease Cancer
Biotin-Gastrin Releasing Peptide, human is a biotinylated gastrin releasing peptide (GRP). Gastrin-releasing peptide (GRP) is a neuropeptide with growth-stimulatory and tumorigenic properties .

HY-P1593

*Mini Gastrin* I, human**	Cholecystokinin Receptor	Endocrinology Cancer
Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

HY-P1593A

*Mini Gastrin* I, human TFA**	Cholecystokinin Receptor	Endocrinology Cancer
Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

HY-P10063

Cionin	Drug Derivative	Metabolic Disease
Cionin is a disulfotyrosyl hybrid of cholecystokinin and gastrin .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-P11768

AMBA	Bombesin Receptor	Cancer
AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand with a human IC₅₀ of 0.82 nM and a human K_i of 0.65 nM. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer .

HY-P11408

[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14)	Bombesin Receptor	Neurological Disease Cancer
[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14), a synthetic peptide, is a non-selective bombesin receptor agonist. [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) has preferred pEC₅₀ values of 8.06 for the neurotrophin B bombesin receptor (BB1), 8.69 for the gastrin-releasing peptide bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) can be used to study diseases related to bombesin receptors, such as cancer and neurological disorders .

Recombinant Proteins Recommended:

Gastrin

Species:	Human (1) Mouse (1) Canine (1)
Tag:	Strep (1) Fc (2)
Source:	HEK293 (2) E. coli Cell-free (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78703

	Gastrin-71 Protein, Mouse (HEK293, Fc) gastrin-71; gastrin; GAST; gastrin component	Mouse	HEK293
	Gastrin-71 protein acts as a potent stimulator of various physiological processes. It activates the gastric mucosa, promotes the production and secretion of hydrochloric acid, and induces the release of digestive enzymes from the pancreas. Gastrin-71 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Gastrin-71 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700868

	GRP-10 Protein, Canine (HEK293, hFc) gastrin-releasing peptide; GRP	Canine	HEK293
	GRP-10 Protein, Canine (HEK293, hFc) is the recombinant canine-derived GRP-10 protein, expressed by HEK293, with C-hFc labeled tag.

HY-P790077

	GRPR Protein, Human (Cell-free, Twin-Strep) GRP-R; GRPR; gastrin-releasing peptide receptor	Human	E. coli Cell-free
	GRPR Protein, Human (Cell-free, Twin-Strep) is the recombinant human-derived GRPR, expressed by E. coli Cell-free , with C-Twin-Strep labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (3)
Reactivity:	Human (3)
Application:	IHC-P (3) ICC/IF (3) ELISA (3)
Isotype:	IgG3 (1) IgG1 (1) IgG2b (1)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (3)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86036

	Gastrin Antibody (YA5728) gastrin [Cleaved into: gastrin-71; gastrin component I; gastrin-52; G52; Big gastrin; gastrin component II; gastrin-34; G34; gastrin; gastrin component III; gastrin-17; G17; gastrin-14; G14; gastrin-6; G6; ]	IHC-P, ICC/IF, ELISA	Human
	Gastrin Antibody (YA5728) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Gastrin.

HY-P85974

	Gastrin Antibody (YA5666)	IHC-P, ICC/IF, ELISA	Human
	Gastrin Antibody (YA5666) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Gastrin.

HY-P85993

	Gastrin Antibody (YA5685)	IHC-P, ICC/IF, ELISA	Human
	Gastrin Antibody (YA5685) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Gastrin.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

gastrin

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products